CLAUDIA GOLDENSTEIN SCHAINBERG
Projetos de Pesquisa
Unidades Organizacionais
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
43 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 43
conferenceObject Behcet's Disease Activity: An Important Factor For Immunogenicity Of Unadjuvanted Influenza A/H1N1 Vaccine(2013) PRADO, Leandro L.; SAAD, Carla G. S.; MORAES, Julio C. B.; RIBEIRO, Ana Cristina Medeiros; AIKAWA, Nadia E.; SILVA, Clovis A.; SCHAINBERG, Claudia G.; SAMPAIO-BARROS, Percival D.; PRECIOSO, Alexander R.; ISHIDA, Maria A.; BONFA, Eloisa; GONCALVES, CelioconferenceObject OBSERVATIONAL STUDY OF SWITCHING ANTI-TNF AGENTS IN ANKYLOSING SPONDYLITIS: EFFECTIVENESS AND PREDICTORS(2014) SAAD, C. G. S.; SHIMABUCO, A. Y.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C.; BONFA, E.- EARLY SACROILIITIS AND PROGRESSION TO ANKYLOSING SPONDYLITIS IS ASSOCIATED TO POSITIVE HLA-B27 IN JUVENILE SPONDYLOARTHRITIS(2015) PEREZ, M. O.; AIKAWA, N. E.; CARRASCO, S.; SAAD, C. G.; SAMPAIO-BARROS, P. D.; GONCALVES, C. R.; MORAES, J. C. B.; GOLDENSTEIN-SCHAINBERG, C.
- HIGH RATES OF WORK DISABILITY IN PATIENTS WITH PSORIATIC ARTHRITIS(2015) GASPARI, C. N. De; GOLDEINSTEIN-SCHAINBERG, C.; PRETTI, F. Z.; SILVA, T. C. P.; GONCALVES, C. R.; SAMPAIO-BARROS, P. D.; SAAD, C. G. S.; MORAES, J. C. B.
- The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis-2019(2020) RESENDE, Gustavo Gomes; MEIRELLES, Eduardo de Souza; MARQUES, Claudia Diniz Lopes; CHIEREGHIN, Adriano; LYRIO, Andre Marun; XIMENES, Antonio Carlos; SAAD, Carla Goncalves; GONCALVES, Celio Roberto; KOHEM, Charles Lubianca; SCHAINBERG, Claudia Goldenstein; CAMPANHOLO, Cristiano Barbosa; BUENO FILHO, Julio Silvio de Sousa; PIERUCCETTI, Lenise Brandao; KEISERMAN, Mauro Waldemar; YAZBEK, Michel Alexandre; PALOMINOS, Penelope Esther; GONCALVES, Rafaela Silva Guimaraes; LAGE, Ricardo da Cruz; ASSAD, Rodrigo Luppino; BONFIGLIOLI, Rubens; ANTI, Sonia Maria Alvarenga; CARNEIRO, Sueli; OLIVEIRA, Thauana Luiza; AZEVEDO, Valderilio Feijo; BIANCHI, Washington Alves; BERNARDO, Wanderley Marques; PINHEIRO, Marcelo de Medeiros; SAMPAIO-BARROS, Percival DegravaSpondyloarthritis is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. The classification axial spondyloarthritis is adopted when the spine and/or the sacroiliac joints are predominantly involved. This version of recommendations replaces the previous guidelines published in May 2013. A systematic literature review was performed, and two hundred thirty-seven studies were selected and used to formulate 29 recommendations answering 15 clinical questions, which were divided into four sections: diagnosis, non-pharmacological therapy, conventional drug therapy and biological therapy. For each recommendation the level of evidence supporting (highest available), the strength grade according to Oxford, and the degree of expert agreement (inter-rater reliability) is informed. These guidelines bring evidence-based information on clinical management of axial SpA patients, including, diagnosis, treatment, and prognosis.
article 31 Citação(ões) na Scopus Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis(2014) FAVARATO, M. H.; MEASE, P.; GONCALVES, C. R.; SAAD, C. Goncalves; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.Objective New evidence has lightened the linkage between psoriatic arthritis (PsA) and the development of atherosclerosis and cardiovascular disease (CVD). We aimed to describe the prevalence of cardiovascular events and associated risk factors among patients with PsA. Methods Retrospective evaluation of medical records from consecutive PsA patients who fulfilled the CASPAR criteria for PsA attending a specialised spondyloarthritis clinic at a single referral centre. CVD was defined based on the occurrence of coronary artery disease (CAD) or cerebrovascular ischaemic disease events. Results We evaluated 158 PsA patients, 48.7% females and 51.3% males, aged 53.7+/-13.9 yrs. Mean PsA duration was 13.7+/-8.9 yrs and polyarticular subtype affected 66(42%) patients. According to drug therapy, 85 (54%) were using NSAIDs and 21 (13%) low-dose prednisone; 32 (20%) were on anti-TNF agents, 94 (60%) metothrexate, 18 (11%) leflunomide, 13 (8%) sulfasalazine, 5 (3%) other immunossupressors and 4 (2.5%) were on chloroquine. Over half patients (87, 55%) had arterial hypertension (AH); 51 (32%) had dyslipidaemia (DLP), 38 (29%) hypertriglyceridaemia and 36(23%) diabetes mellitus (DM). Lipid profile was similar for both genders with mean total cholesterol= 186.5+/-38.6mg/dl, LDL=112.3+/-30.6 mg/dl, HDL=47.89+/-14.6 and triglycerides=127.4+/-65.6 mg/dl. Of note, 14% PsA patients have had CVD, namely cerebrovascular or coronary heart disease. Sex, age, disease duration, joint involvement subtype, disease activity, CRP and lipid levels were similar among patients with and without CVD. The prevalence of All (95% vs. 45%, p<0.001), DLP (75% vs. 27.7%, p<0.001) and DM (60% vs. 19%, p<0.001) were significantly greater in PsA patients who have had CVD compared to those without CVD, conferring an odds ratio of 21.0 for All and of 5.4 for DM. Conclusion The high prevalence of CVD in PsA patients is influenced by increased All and DM. Hence early recognition and specific treatment is mandatory in order to reduce the risk for CVD, avoiding early morbidity and mortality.conferenceObject A CROSS-SECTIONAL EVALUATION OF A BRAZILIAN SPONDYLOARTHRITIS SINGLE-CENTER TERTIARY COHORT: CLINICAL AND TREATMENT DATA(2018) SHIMABUCO, A.; MORAES, J. C. B. de; SAMPAIO-BARROS, P.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C. R.; SAAD, C. G. S.conferenceObject INFLUENCE OF SULFASALAZINE COMEDICATION IN SWITCHING AND RESPONSE TO ANTI-TUMORAL NECROSIS FACTOR IN ANKYLOSING SPONDYLITIS(2016) SHIMABUCO, A. Y.; GONCALVES, C. R.; MORAES, J. C. B.; WAISBERG, M. G.; RIBEIRO, A. C. M.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; BONFA, E.; SAAD, C. G. S.conferenceObject Metabolic Syndrome in Patients with Psoriatic Arthritis Is Associated to Peripheral Disease Activity(2015) GASPARI, Camilla De; MORAES, Julio C. B.; SAMPAIO-BARROS, Percival D.; GONCALVES, Celio R.; SAAD, Carla G. S.; GOLDENSTEIN-SCHAINBERG, Claudia- Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis(2013) AIKAWA, N. E.; CAMPOS, L. M. A.; GOLDENSTEIN-SCHAINBERG, C.; SAAD, C. G. S.; RIBEIRO, A. C.; BUENO, C.; PRECIOSO, A. R.; TIMENETSKY, MdoC; SILVA, C. A. A.; BONFA, E.Objectives: To assess the vaccine response in juvenile idiopathic arthritis (JIA) as an extension of previous observation of immunogenicity and safety of a non-adjuvanted influenza A H1N1/2009 vaccine in a large population of juvenile rheumatic diseases. Moreover, to assess the possible influence of demographic data, disease subtypes, disease activity, and treatment on immunogenicity and the potential deleterious effect of the vaccine in the disease itself, particularly in the number of arthritis and inflammatory markers. Methods: A total of 95 patients with JIA and 91 healthy controls were evaluated before and 21 days after vaccination, and serology for anti-H1N1 was performed by haemagglutination inhibition assay (HIA). Patient and physician visual analogue scales (VAS), Childhood Health Assessment Questionnaire (CHAQ), number of active joints, acute phase reactants, and treatments were evaluated before and after vaccination. Adverse events were also reported. Results: JIA patients and controls were comparable regarding mean current age (14.9 +/- 3.2 vs. 14.6 +/- 3.7 years, p = 0.182). After vaccination, the seroconversion rate was significantly lower in JIA patients compared to controls (83.2% vs. 95.6%, p = 0.008), particularly in the polyarticular subtype (80% vs. 95.6%, p = 0.0098). Of note, JIA subtypes, number of active joints, acute phase reactants, CHAQ, patient and physician VAS, and use of disease-modifying anti-rheumatic drugs (DMARDs)/immunosuppressive drugs were similar between seroconverted and non-seroconverted patients (p > 0.05). Regarding vaccine safety, no deterioration was observed in the number of active joints and acute phase reactants during the study period. Conclusion: Influenza A H1N1/2009 vaccination in JIA induces a lower but effective protective antibody response probably independent of disease parameters and treatment with an adequate disease safety profile.